WASHINGTON D.C. (June 16, 2022) – A new PhRMA and Ipsos poll of over 2,500 Americans finds that when it comes to health care, most registered voters are concerned about issues related to health insurance coverage and costs. Many voters voice concerns over their ability to afford their out-of-pocket heath care costs and the majority agree that navigating their insurance coverage is too complicated. Additionally, when voters are presented with information about pharmacy benefit managers (PBMs) concern grows, especially among seniors. To lower the cost of health care in this country, voters support solutions that ensure greater accountability from health insurance companies and PBMs. Eighty-three percent of voters support requiring health insurers and pharmacy benefit managers to share more of the rebates and discounts they receive directly with patients, so they pay less for their medicines.
Health insurance costs and coverage rank as the most important health care issue among registered voters.
Many voters are concerned with how health insurers and PBMs affect patient access and affordability.
And when registered voters are presented with information about PBMs, they are more likely to voice concerns about their role and impact on patients’ access to medicines.
Registered voters expressed support for policy solutions that ensure greater accountability from health insurance companies and PBMs—such as improving transparency and predictability in health care costs and requiring discounts on medicines to be shared directly with patients at the pharmacy counter.
The poll was conducted among 2,514 American adults using Ipsos’ probability based KnowledgePanel®, and it is representative of the American adult population. The margin of sampling error is plus or minus 2.2 percentage points at the 95% confidence level, for results based on the entire sample of adults.
For complete results, please download the fully annotated questionnaire.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Over the last decade, PhRMA member companies have more than doubled their annual investment in the search for new treatments and cures, including nearly $101 billion in 2022 alone.